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INTRODUCTION 
The lesions of prostate are responsible for significant morbidity and 
mortality among the males worldwide (1).The age range of males presenting 
with symptoms due to prostatic lesions is 40- 90 years, with majority of the 
cases were in the age group of 60 – 70 years (1). 
Prostatic lesions are broadly categorized as inflammatory and 
neoplastic lesions. The neoplastic lesions are inturn subclassified as benign, in 
situ and malignant lesions . 
Prostate cancer is the most aggressive malignant neoplasm with varied 
clinical presentations. This tumor does not show any warning signs in its early 
course of development. 
The most widely used screening test for detecting prostatic cancer is the 
measurement of serum Prostate specific antigen (PSA) level , in conjunction 
with digital rectal examination for all the suspected cases. 
Prostate Specific antigen is secreted by normal and malignant prostatic 
epithelial cells. Therefore their level in the serum increases significantly in 
men with prostate cancer. Though it gives the suspicion for the underlying 
tumor, it isnot specific.There are many benign conditions like benign prostatic 
hyperplasia and prostatitis which increases the serum PSA levels.Therefore it 
is of at most significance to use a newer marker to identify the prostatic cancer 
at an early stage. 
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 Cluster of Differentiation (CD) 10, also known as Common Acute 
Lymphoblastic Leukemia Antigen (CALLA) was first described on human 
leucocytes (20). Several studies on CD10 revealed that it is not only seen in 
lymphocytes, but also found to be expressed in other human cells both in 
normal and in pathological states. 
Regarding the prostate gland, CD10 is expressed constantly in the 
apical luminal surface of the normal prostatic epithelial cells. In various 
lesions of prostate the pattern of expression varies ranging from altered 
expression to loss of expression. 
In prostatic cells CD 10 acts as a transmembrane peptidase .It plays an 
important role in the pathogenesis of prostatic cancer. Generally it cleaves the 
excessive growth factor from the stroma thereby it prevents the continuous 
and unwanted growth in the luminal epithelial cells. 
Literature review shows that loss of CD10 expression is seen in lower 
Gleason score prostatic tumors whereas increased and altered expression in 
high Gleason score tumors, lymph node metastasis and in bone metastatic 
prostatic carcinoma. This concept signifies the use of CD10 as a diagnostic 
and prognostic marker in prostatic carcinoma.  
Based on this we are analysing the expression of CD 10 in a various 
pathological conditions of prostate. 
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AIMS AND OBJECTIVES 
 
1.  To identify the expression of CD 10 in the lesions of prostate. 
2.  To analyse the pattern of expression (membranous, cytoplasm, both). 
3.  To correlate the expression of CD10 with the age of the prostatic 
carcinoma patients. 
4. To correlate the expression of CD10 with histopathological grading and 
serum PSA level of prostatic carcinoma. 
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REVIEW OF LITERATURE 
ANATOMY: 
The prostate is an exocrine gland constituting an important organ of 
male reproductive system. 
It is located in the pelvis just below the urinary bladder encompasses 
the urethra and in front of the rectum. 
It is a walnut shaped organ and its average weight is around 11-16 
grams. 
Anatomically it is divided into 5 lobes namely anterior, posterior, 2 
lateral lobes  and one median lobe but widely used terms are three zones 
namely peripheral zone, central zone, transitional zone. 
 
Figure 1: Zones of prostate 
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The transition zone surrounds the prostatic urethra; central zone that 
lies posterior to the transition zone encircles the ejaculatory duct. Peripheral 
zone forms the main bulk of the gland. 
Each zone has got its own significance. Prostatic cancer usually arises 
from the peripheral zone and prostatic hyperplasia from the transition zone. 
This anatomical knowledge is important because any lesion in a 
particular zone can give a clue to the underlying pathology. 
VASCULAR AND NERVE SUPPLY: 
The arterial supply of prostate gland is through the Internal pudendal 
artery, inferior vesical artery and branches of middle rectal artery. 
The blood from the prostatic gland drains via the vesico prostatic 
plexsus to the internal iliac veins. These plexus are particularly strong under 
the puboprostatic ligaments  
The autonomic innervation reaches the prostate gland together with the 
arterial branches and perforates the capsule of the prostate. Parasympathetic 
signals stimulate glandular activity and the sympathetic innervation of α1-
receptors mediates smooth muscle contraction. 
The lymphatic vessels of the prostate gland drains to external iliac 
lymph nodes and internal iliac lymph nodes. 
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HISTOLOGY: 
Prostatic gland is mainly composed of branching duct, acinar glands 
embedded in dense fibromuscular stroma. 
Prostatic glands show mild convolutions. It is lined by 2 layers of 
epithelial cells. Inner tall columnar cells with basally located nucleus that 
performs the secretory function and the outer layer of flattened basal cells. 
Functions: 
The gland secretes milky white colour fluid that constitutes around 30% 
of volume of the semen.It is alkaline in nature. Its function is to preserve the 
sperm and maintain its motility, and also neutralizes the acidity of the vagina. 
EPIDEMIOLOGY OF PROSTATIC LESIONS: 
 Benign prostatic hyperplasia is the most common benign neoplastic 
lesion of prostate of aging men. It poses major public health problem causing 
significant morbidity thereby affecting quality of life of aging men. 
The prevalence of BPH increases with increasing age.It is about 8% in 
the age group of 30 to40 years and 50% and 80% in the 8th and 9th decade 
respectively. The risk of developing BPH in men aged 70 -79 years are  
4.6 times higher than those of 40 – 49 of age. In India the incidence of BPH is 
around 92.97%. It has been estimated that the doubling time of BPH growth is 
7 
 
4.5 years around the age group of 35- 50 and 10 years for the age range of  
51 – 70(4) 
Prostate cancer is the second most common cause of cancer (1) and the 
sixth leading cause of cancer death among men worldwide (2). The worldwide 
prostate cancer  burden is expected to grow to 1.7 million new cases and  
499 000 new deaths by 2030 simply due to the growth and aging of the global 
population. 
The incidence rates of prostate cancer are considered low in Asian and 
North African countries, ranging from 1 to 9/100,000 persons.The prevalence 
of prostate cancer in India is far lower as compared to the western countries 
but with the increased migration of rural population to the urban areas, 
changing life styles, increased awareness, and easy access to medical facility, 
more cases of prostate cancer are being picked up. The data regarding the 
exact incidence of prostate cancer in India is limited mainly because of the fact 
that it is not a notifiable disease and only limited population based cancer 
registries are available in India. 
In India, when comparing the incidence rates of different cancers, there 
is a highest incidence of oral cancers and lowest incidence and prostate 
cancers (3). The estimated incidence of prostate cancer in India is around 
3.75/100,000 persons. The incidence rate varies among the major cities in 
India. It is highest in the metrocities like in Delhi, the rate being 10.9%, in 
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Chennai it is 4.2% and lowest in northeast India like in Manipur the rate being 
0.8%.(4) 
ETIOPATHOGENESIS FOR PROSTATIC LESIONS: 
The major proven risk factors for prostatic lesions are age, hormonal 
factors and family history. Considering the importance of prostatic malignancy 
detailed analysis of risk factors of prostatic carcinoma are as follows.   
AGE: 
As the age advances the risk for prostate cancer also increases. The risk 
for prostate cancer begins to rise after 55 years and it peaks at around 70 and 
declines thereafter (6). According to statistics of United States of America it 
was estimated that every one in 10,000 men in their 40s and one in 15 men in 
their 60s will be affected by prostate cancer. 
FAMILY HISTORY:  
An individual with a positive family history has a significant risk in 
developing prostate cancer. In a family if there is a first degree relative 
(brother or father) with prostatic cancer then there is 2 to 3 fold risk for the 
individual to develop the same. It is further increased by the early age at 
onsetin relative or multiple relatives with the disease (5).Whole genome or 
partial genome analysis by linkage mapping studies among the high risk 
pedigrees revealed many prostatic cancer specific foci.Several studies 
onfamilial prostate cancer describes the pattern of inheritance of high risk 
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genes. It states that those high risk genes responsible for cancer follows 
Mendelian Autosomal dominant expression thereby results in early age of 
onset of the disease (12) 
RACE: 
Incidence rate for African American is much higher, around 60 fold 
when compared to men in Asian countries. This variations are mainly due to 
the screening programmes, diagnostic advancement, increase accessibility to 
total health care services etc.  Migrants from Asian countries also shows 
similar incidence rate of prostatic cancer to that of Americans. It is the 
environmental factors prevailing in that region contributing to the 
development of cancer (13) 
DIET: 
Diet constituting large amounts of fat and increased intake of total 
calories is associated with the increased risk. Reduced intake of antioxidant 
like selenium, vitamin C, plays a significant role in the development of cancer. 
Vitamin D deficiency has been identified as one of the possible risk 
factors for prostatic carcinoma. Increased age, black race and northern 
latitudes which was proved as an independent risk factors, are all associated 
with Vitamin D deficiency. 
Possible explanations are increased age is associated with decreased 
synthesis of Vitamin D and also partly due to decreased exposure to sunlight. 
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In black race there is more melanin pigments which can directly inhibits the 
synthesis of vitamin D. When compared to Americans, Asian men have 
decreased incidence rate of prostatic carcinoma again can be associated with 
their dietary habits. Asian diet constitute rich in fish that has higher amount of 
Vitamin D (66). 
 
Figure 2: Hypothesised model of prostate cancer in relation to  
vitamin D deficiency 
 
Other less important factors are anthropometric factors, hormonal 
profiles, and other co-morbid health factors. They play a minor role in the 
development and progression of the disease. 
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ANTHROPOMETRIC FACTORS: 
 Anthropometric factors like height and obesity and their association 
with prostate cancer risk has been extensively studied. It was hypothesized 
that adult height is due to the hormone Insulin like growth factor. This 
hormone carries significant risk for the development of prostate cancer. 
Regarding obesity, it was hypothesized that increased obesity reduces sex 
hormone binding globulins, therefore more availability of free sex hormones 
in the circulation which can stimulate cancer progression (14). But both the 
hypothesis has not been proved so far. 
 
Figure 3: List of risk factors in prostate cancer (14)  
+ indicates positive association, - indicates inverse association 
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An increased level of IGF-1 that mediates the action of growth 
hormone was identified as a independent risk factor for prostate cancer. It was 
proven that administration of IGF-1 promotes growth of prostate and tumor 
development in animal models (15) 
PATHOGENESIS: 
 It is the hormone dihydrotestosterone plays a major role in the 
development of prostatic lesions including benign and malignant lesions. 
BPH is characterized by increase in the epithelial and stromal cells 
commonly in the periurethral zone of prostate.This increased cell number 
could be due to either increased proliferation of cells or decreased  
apoptosis (67). 
 
Figure 4 : Pathogenesis of BPH 
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Dihydrotestosterone (DHT) which is the active metabolite of hormone 
testosterone is the main androgen responsible for development of BPH.  
The stromal cells of prostate gland convert testosterone into DHT 
through the enzymatic action of 5 Alpha reductase. This DHT is more potent 
and has more affinity towards Androgen receptor when compared to hormone 
testosterone. It binds to the androgen receptor (AR) of epithelial and stromal 
cells thereby stimulating transcription of genes resulting in proliferation of 
epithelial cells and stromal cells. 
 
Figure 5: DHT and nuclear transcription. 
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Though the pathogenesis for the BPH has been well understood, the 
exact triggering or inciting event is still not clear. One possible hypothesis is 
that prostatic inflammation could be a triggering factor for the cell 
proliferation (16). Inflammatory cytokines such as Interleukin 2, Interleukin 6, 
interleukin 8, interleukin 15 and Interferon alpha causes tissue damage and 
oxidative stress to the stromal cells. This leads to compensatory cellular 
proliferation thereby promoting the growth of the gland. (19). 
In case of prostatic carcinoma these circulating androgens are essential 
for the onset of prostate cancer through their interactions with Androgen 
receptor. Therefore surgical treatment like bilateral removal of testes which is 
the source for androgens and antiandrogen drugs causes disease regression. 
But some of the tumors become androgen resistant by following mechanisms: 
(I) Androgen receptor gene (AR) amplification results in 
hypersensitivity to even low levels of androgens. 
(II) Mutation in androgen receptor gene causing ligand independent 
AR activation. 
 In addition to the androgens, prostatic cancer usually acquires large 
number of genetic alterations including point mutations, deletions, 
amplifications and translocations. There are prostate cancer specific 
chromosomere arrangements. It commonly involves E26 Transformation 
specific (ETS) gene family. ERG (ETS-related gene product) is the oncogene 
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which belongs to the ETS family, fuses with Transmembrane protease serine 2 
(TMPRSS2) resulting in Androgen independent tumor progression. This 
results in overexpression of transcription factors that causes upregulation of 
matrix metalloproteinase. Increased matrix metalloproteinase makes the 
malignant prostatic epithelial cells more invasive. 
Benign prostatic hyperplasia (BPH) and normal epithelium are negative 
for ERG rearrangements and fusion transcripts. TMPRSS2: ERG fusions are 
reported in 10 – 21% of high grade prostatic intraepithelial neoplastic  
lesions (17) and 29 – 59 % in hormone refractory and metastatic prostatic 
carcinoma. (18) 
Other common genetic alterations in prostate cancer includes mutation 
in BRCA 2 and PTEN tumor suppressor gene, MYC oncogene and at later 
stages TP53 and RB gene mutations. 
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Figure 6: Pathogenesis of prostatic carcinoma 
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COMMON DISEASES OF PROSTATE: 
1. INFLAMMATION: 
Inflammation of the prostate is known as prostatitis. Presenceof 
inflammatory cells in the prostate is commonly seen in the biopsy specimen. 
Prostatitis is further divided into asymptomatic inflammatory prostatitis, acute 
prostatitis and granulomatous prostatitis. 
Acute prostatits:  
It most commonly results from ascending infection from urethra, 
bladder and epididymis. Patient often presents with acute symptoms like fever, 
dysuria, urinary urgency intense pelvic pain. Microscopically prostatic biopsy 
composed of neutrophils in the glandular lumen and macrophages in the 
stroma. It cannot be diagnosed by histology alone. Often combined clinical 
picture, urine culture aids in the diagnosis. 
Asymptomatic inflammatory prostatitis: 
It includes the presence of inflammatory cells like neutrophils, 
lymphocytesand histiocytes in the prostate but most of the patients are without 
any clinical symptoms. Since inflammation of the prostate also raises the 
serum PSA level and since the patient is also asymptomatic it can be clinically 
misdiagnosed for prostatic carcinoma.Therefore it is important to mention in 
the biopsy report. Inflammation is commonly associated with benign prostatic 
hyperplasia. 
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Granulomatous inflammation: 
Granulomatous prostatitis is a rare entity. This inflammation is due to 
the release of prostatic secretions into the stroma. It elicits the granulomatous 
reaction in the prostate. This condition is also seen in postbiopsy, after 
instillation of BCG injection into the bladder for bladder carcinoma patients. 
Histologically it is composed of granulomas destroying the glands often 
associated with multinucleated giant cells, histiocytes, lymphocytes and 
plasma cells. Differential diagnosis could be tuberculosis which often consists 
of caseating necrosis or could be of fungal etiology, metastatic deposits which 
are very rare causes. 
2. METAPLASIA: 
Metaplasia of prostatic epithelium is a secondary phenomenon.It occurs 
in response to inflammation or injury.Various metaplasias in prostate are 
squamous, eosinophilic, mucinous, urothelial etc. Reversibility of these 
metaplasias is very unlikely. These changes are not the preneoplastic 
conditions. 
Squamous metaplasia: It is most commonly an incidental finding. This is 
mostly a secondary phenomenon due to infarction of the usual nodular 
hyperplasia, or after post hormonal and radiotherapy for prostatic carcinoma. 
Histologically it is composed of nests of squamous epithelium with adjacent 
areas of infarction.The main differential diagnosis could be Squamous cell 
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carcinoma and Urothelial carcinoma which shows more cytological atypia and 
stromal invasion. 
Mucinous metaplasia: It is very rare entity composed of acini lined by tall 
columnar cells filled with mucin secretion with basally located nucleus. 
Clinical significance is that it can mimic adenocarcinoma prostate which 
should be differentiated by the lack of infiltrative nature, cytological atypia, 
and presence of basal cells 
Urothelial metaplasia: It is defined as urothelial lining the prostatic acini and 
larger ducts. It is a great mimicker of Urothelial carcinoma spreading via 
prostatic ducts. Cytologically these two conditions can be differentiated by the 
presence of nuclear atypia in malignancy and also with the help of 
immunohistochemistry. Other differential diagnosis is high grade prostatic 
intraepithelial neoplasia that shows prominent nucleoli. 
3. HYPERPLASIA: 
Hyperplasia of the prostate includes both epithelial and stromal cell 
proliferation. It is a benign condition. It includes 
a. Usual nodular hyperplasia: 
It is the most common microscopic finding in the patient clinically 
diagnosed of BPH. It commonly arises from the transition zone and 
periurethralzone. This causes urethral obstruction leading to urinary 
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symptoms. It is composed of glandular and stromalelements with varied 
percentage. The glands are more complex with prominent luminal infoldings. 
Cystic dilatation of glands can also occur. 
b. Basal cell hyperplasia: 
This subtype includes the proliferation of basal cells. It defines the 
presence of two or more layers of basal cells with scant cytoplasm around the 
prostatic ducts and acini. 
PROSTATIC INTRAEPITHELIAL NEOPLASIA: 
It is the proliferation of epithelial cells with features of atypia in the 
ducts and acini. 
Originally PIN was classified as grade I, II, III, according to increasing 
degrees of abnormality. Nowadays it is been termed as low grade PIN (grade 
I) and high grade PIN (grade II, III) 
Low grade PIN was formerly known as mild dysplasia. LGPIN mostly 
do not progress and carries no significance for the subsequent development of 
prostatic carcinoma. Microscopically the glands show complex architecture 
with intact basal cell layer and cellular stratification. Cytologically the cells 
have eosinophilic cytoplasm with enlarged nuclei with increased variability in 
nuclear size and nuclear hyperchromasia and indistinct nucleoli. 
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High grade PIN has epithelial cell proliferation in four different 
architectural patterns: Tufting, micropapillary, cribriform and flat. Regarding 
the basal cells, high grade PIN shows reduced number of basal cells. 
When nuclear features are taken into consideration High grade PIN has 
increased nuclear atypia and prominent nucleoli. 
The significance of reporting high grade PIN is that the patients should 
be considered for rebiopsy (time interval for rebiopsy not standardised) and 
they are at increased risk of development of carcinoma. 
PROSTATIC CARCINOMA: 
 Prostatic carcinoma causes significant morbidity among elderly 
individuals. It has been classified by WHO 2016 as follows.  
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF  
PROSTATE  (2016) 
EPITHELIAL TUMOURS 
Adenocarcinoma(acinar) 
o Atrophic 
o Pseudohyperplastic 
o foamy 
o colloid 
o Signet ring 
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o Microcystic variant 
o Pleomorphic giant cell adenocarcinoma 
o Sarcomatoid carcinoma 
Prostatic intraepithelial neoplasia (PIN), High grade 
Intraductal carcinoma NOS 
Ductal adenocarcinoma 
 Cribriform 
 Papillary 
 Solid 
Urothelial tumors 
Urothelial carcinoma 
Squamous tumors 
Adenosquamous carcinoma 
Squamous cell carcinoma 
BASAL CELL TUMOURS 
Basal cell adenoma 
Basal cell carcinoma 
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NEUROENDOCRINE TUMOURS: 
Adenocarcinoma with Neuroendocrine differentiation 
Well differentiated neuroendocrine tumor 
Small cell neuroendocrine carcinoma 
Large cell neuroendocrine carcinoma 
MESENCHYMAL TUMOURS 
Stromal tumor of uncertain malignant potential 
Stromal sarcoma 
Leiomyosarcoma 
Rhabdomyosarcoma 
Chondrosarcoma 
Angiosarcoma 
Synovial sarcoma 
Inflammatory myofibroblastic tumour 
Osteosarcoma 
Undifferentiated pleomorphic sarcoma 
Hemangioma 
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Chondroma 
Leiomyoma 
Granular cell tumor 
Solitary fibrous tumor 
Solitary fibrous tumor , Malignant 
HEMATOLYMPHOID TUMORS 
Diffuse Large B cell lymphoma 
Chronic lymphocytic leukemia/ Small lymphocytic lymphoma 
Follicular lymphoma 
Mantle cell lymphoma 
Acute myeloid leukemia 
B lymphoblastic leukemia/Lymphoma 
MISCELLANEOUS TUMOUR 
Cystadenoma 
Nephroblastoma 
Rhabdoidtumor 
Germ cell tumors 
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Clear cell adenocarcinoma 
Melanoma 
Paraganglioma 
Neuroblastoma 
SECONDARY/METASTATIC TUMOUR 
NEWER ENTITY ADDED IN WHO 2016: 
 Intraductal carcinoma 
 New variants of acinar adenocarcinoma 
Microcystic variant  
  Pleomorphic large cell variant 
 Large Cell carcinoma of prostate 
Though we have numerous histological classification of prostatic 
tumor, the term prostatic carcinoma commonly refers to prostatic 
adenocarcinoma. 
 Prostatic adenocarcinoma usually arises in the peripheral zone of 
prostate gland. Grossly the tumor is grey white, irregular or nodular in 
appearance. 
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 Histologically prostatic adenocarcinoma is characterised by abnormal 
glandular architectural pattern with single layer of epithelial cells and with 
absence of basal cells.  
Numerous variants of acinar adenocarcinoma have been described. 
Microcystic variant and Pleomorphic giant cell variant are the newly added 
entity in WHO 2016 blue book. 
VARIANTS OF PROSTATE ACINAR ADENOCARCINOMA: 
ATROPHIC VARIANT:  
Atrophic variant is a rare entity. The criteria to report this entity is 
presence of malignant atrophic glands occupying at least 50 % of the tumor. 
The glands should be of infiltrative nature. The glands are lined by flattened 
cells with scant cytoplasm and hyperchromatic nuclei with prominent nucleoli. 
This variant has been graded as Gleason pattern 3 or 4 and grouped under 
moderately differentiated carcinoma. 
PSEUDOHYPERPLASTIC VARIANT:  
The glands are benign looking ,dilated with papillary infoldings but 
show malignant cytological features like enlarged hyperchromatic nuclei with 
prominent nucleoli. Mostly graded as Gleason’s grade 3 and generally has 
good prognosis. (53) 
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FOAMY GLAND VARIANT:  
The glands will have foamy appearance with round pinpoint nuclei 
rather than prominent hyperchromatic features. Infiltrative nature of glands 
proves a diagnostic feature. It has got a good prognosis and mostly comes 
under Gleason’s grade 3 (54) 
MUCINOUS VARIANT: 
 Atleast 25% of the tumor should have aggregates of tumor cells 
floating in mucin lakes. No significant intracellular mucin is seen.This variant 
has to be differentiated from metastasis before diagnosing the same. These 
tumors are given Gleason grade 4 and considered as aggressive variant. Since 
only few cases have been reported the exact behavior is not known (51) 
SIGNET RING VARIANT: 
 25% of the tumor should have single cells with intracellular mucin 
vacuole that pushes the nuclei to the periphery.This need to be differentiated 
from metastasis. It is assigned Gleason grade 5 and has aggressive behavior. It 
is regarded as high grade adenocarcinoma with poor patient survival. (52) 
MICROCYTSIC VARIANT: 
It is composed of cystically dilated glands with gland diameter 10 times 
more than that of malignant acinar glands. Nuclear atypia is difficult to assess 
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in atrophied cells due to cystic dilatation of the glands. It has been graded as 
Gleason 2 or 3, with favorable prognosis (55) 
PLEOMORPHIC GIANT CELL VARIANT:  
It is the highly aggressive variant of adenocarcinoma composed of giant 
cells with marked pleomorphism, lack of cohesiveness and areas of extensive 
necrosis (56). It has a poor outcome and generally assigned high Gleason 
score 9 or 10. 
The different architectural patterns forms the basis for Gleason’s 
grading system which forms the important prognostic factor in the 
management of prostatic carcinoma. It is the most commonly used grading 
system which consists of five basic grades. The original Gleason’s grading 
system was developed by Dr. Donald Gleason, who is a pathologist worked at 
Minneapolis Veterans Affairs Hospital. He developed it in the year 1965 (45) 
 Then it underwent several modifications and popularly called as 
modified Gleason’s grading system. It was first modified by International 
Society of Urological Pathology (ISUP) consensus meeting in the year 2005 
(46). Again in the year 2014 ISUP Prostate Cancer Grading Panel consensus 
meeting made further alterations. 
 Grade 1 and 2 encloses well differentiated tumor. It is composed of 
well circumscribed nodules of closely packed small glands of uniform sizes. 
The stroma in between the glands is more in case of grade 2. 
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 Grade 3: It is the most common grade and considered as well 
differentiated grade like grades 1 and 2. It consists of small and irregularly 
dilated infiltrating individual glands with wide stromal separation. The cells 
are darker when compared to the normal epithelial cells. WHO 2016 includes 
microcystic and pesudohyperplastic glands in this grade and removed 
cribriform glands from this grade. 
 Grade 4 consists of attempted glandular formation glands fusion, glands 
with cribriform pattern and glands with glomeruloid pattern. 
 Grade 5 composed of sheets, cords and in single cells. WHO 2016 also 
includes linear arrays, solid nests which was not recognized by WHO 2004. 
Post hormonal and post radiotherapy tumors are excluded from Gleason’s 
grading. 
EVOLUTION OF GLEASON GRADING: 
Donald Gleason included cribriform pattern of glands in both grade 3 
and grade 4. He doesn’t forms a strict criteria to differentiate cribriform 
pattern of Gleason grade3 from Gleason grade 4. 
In 2005 ISUP modified and developed strict criteria to overcome the 
above difficulties. 
Cribriform Grade 3 : It includes small round glands with round contours 
with evenly spaced round lumens. 
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Cribriform Grade 4: It includes irregular gland with irregular contours with 
irreguilar lumens or slit like lumensunder pattern 4. 
 According to 2014 ISUP modification all the cribriform pattern are 
considered as grade 4. 
Newer modifications in Gleasons grading system in WHO 2016 are as 
follows: 
1. All cribriform patterns are grouped under pattern 4. 
2. Glomeruloid pattern gouped under pattern 4. 
3. Mucinous adenocarcinoma may be pattern 3 or pattern 4. 
4. Intraductal carcinoma not to be graded. 
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Figure 7: Evolution of Gleason grading system 
(a) Original Gleasom grading system 
(b) 2005 ISUP Modification of Gleason grading system 
(c) 2014 Isup Modificationof Gleason grading system 
 
 
(a) (b) (c) 
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Figure 8 : 2016 WHO modified Gleason grading system. 
Reporting of Gleasons grading 
Based on the above patterns in H and E sections the tumors are scored. 
The most predominant pattern is called as primary pattern and the 
second most common pattern is known as secondary pattern  and the least 
pattern is known as tertiary pattern. 
Generally the primary and secondary pattern is added together for 
Gleason’s scoring in cases of radical prostatectomy and TURP specimens. In 
case of needle biopsy the most common grade and worst grades are added 
since underdiagnosis is common in biopsy specimen.  
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The lowest possible Gleason score is 2 (1 + 1), where both the primary 
and secondary patterns have a Gleason grade of 1. 
The highest possible Gleason score is 10 (5 + 5), when the primary and 
secondary patterns both have the most disordered Gleason grades of 5. 
 Based on Gleason’s score prostatic adenocarcinoma is divided into well 
differentiated, moderately differentiated and poorly differentiated tumors. 
Gleason’s score 2- 6 : Well differentiated tumors, with excellent prognosis. 
Gleason’s score 7 (3+4): Moderately differentiated tumors. 
Gleason’s score 7(4+3): Moderately to poorly differentiated tumors. 
Gleason’s score 8 – 10: Poorly to undifferentiated tumors, aggressive in 
nature. 
 Recently based on Gleason’sscore prostatic carcinoma is divided into 5 
prognostic groups by ISUP (International Society of Urologic Pathology).  
The prognostic groups are as follows: 
Grade group 1 (Gleason score 3 + 3 = 6): Only individual discrete well-
formed glands. 
Grade group 2 (Gleason score 3 + 4 = 7): Predominantly well-formed glands 
with lesser component of poorly formed/fused/cribriform glands. 
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Grade group 3 (Gleason score 4 + 3 = 7): Predominantly poorly formed/ 
fused/cribriform glands with lesser component of well-formed glands. 
Grade group 4 (Gleason score 8) - Only poorly formed/fused/cribriform 
glands or predominantly lacking glands and lesser component of well-formed 
glands  
Grade group 5 (Gleason scores 9–10): Lack of gland formation (or with 
necrosis) with or without poorly formed/fused/cribriform glands. 
They analysed that the 5 year risk free survival for grade groups 1 to 5 
are 96%, 88%, 63%, 48% & 26% respectively (fig 9) 
 
Figure 9: Recurrence-free progression following radical prostatectomy 
stratified by grade (green line -Gleason score 6 [Grade 
Group 1], orange –Gleason score 3+4 [Grade Group 2], dark 
blue -Gleason score 4+3 [Grade Group 3], brown –Gleason 
score 8 [Grade Group 4], gray –Gleason score ≥9 [Grade 
Group 5]). 
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RISK STRATIFICATION: 
Based on diagnostic serum PSA level , Gleason score and clinical stage 
of localized prostate cancer, D’Amico et al in the year 1998 (50) proposed risk 
stratification that was included in the WHO 2016 Blue book.  They provide 
better options for treatment recommendations than just using stage of cancer 
alone. It forms the basis for initial treatment for men with prostate cancer and 
it avoids overtreatment for early stage of cancer (49).  
Low risk -Diagnostic PSA <10.0 ng/ml and highest biopsy Gleason score <6 
and  clinical stage T1c or T2a. 
Intermediate risk - Diagnostic PSA >10.0 ng/ml but <20ng/ml or highest 
biopsy Gleason score =7 or clinical stage T2b. 
High risk – Diagnostic biopsy >20 ng/ml or highest biopsy Gleason sc ore >8 
or clinical stage T2c /T3. 
 Thus according to ISUP recommendations It was decided that any 
biopsy report for prostate carcinoma it is mandatory that it should contain 
modified Gleason scoring system and Prognostic groups. Treatment options 
are categorized according to risk stratification. 
PROSTATIC INTRADUCATL CARCINOMA (IDC – P) 
 It is added as a new entity in the recent WHO 2016 classification of 
prostatic cancers.It is the involvementof preexisting ducats by adjacent high 
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grade (Gleason 4 and 5) adenocarcinoma. The basal cells are focally 
preserved. 
Rather than infiltrating borders the edges are smooth. It may have any 
one of the following three architectural and cytological features (57) 
1. Solid cribriform architecture – less than 50 % cribriform spaces 
2. Loose cribriform architecture> 50 % of lumen formation. 
3. Marked nuclear pleomorphism with 6 times larger than the normal and 
associated with comedo necrosis. 
The main differential diagnosis is high grade PIN, which can be 
distinguished from Intraductal carcinoma Prostate by the absence of nuclear 
pleomorphism, comedo necrosis. 
 
Figure 10: proposed model of intraductal carcinoma 
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IMMUNOHISTOCHEMISTRY IN PROSTATIC CARCINOMA: 
 Though predominantly architectural pattern of glands and their 
cytological features helps in differentiating benign and malignant, 
immunohistochemistry proves to be a valuable tool in a subset of cases. 
 There are separate immunostains for basal cells and malignant 
epithelial cells. 
The loss of basal cells is an early and the most important diagnostic 
feature in prostate carcinomas.. The lack of basal cell layer staining must be 
validated against the simultaneous demonstration of a positive basal cell layer 
in adjacentfociof benign glands. Basal cell markers are cytokeratins (CK 
HMW, CK 5/6, CK 14) and p63. 
AMACR (Alpha-methylacyl-CoA racemace) stains the malignant 
epithelial cells.AMACR is a mitochondrial and peroxisomal enzyme that is 
involved in beta-oxidation of branched-chain fatty acids. It is expressed in the 
cytoplasm of malignant epithelial cells. 
It is highly sensitive marker showing positivity in both PIN and 
prostatic carcinoma. 
When it is combinedly used with basal cell markers we can  significantly 
increase the diagnostic accuracy and thereby avoiding unnecessary re-biopsies. 
Prostate-specific antigen (PSA) is widely used marker to confirm the 
prostatic origin of metastatic carcinoma. 
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In case of distinguishing from poorly differentiated prostatic carcinoma 
and poorly differentiated urothelial carcinoma prostatic carcinoma shows 
positivity for PSA, PSAP (prostate specific acid phosphatase) and negative for 
thrombomodulin and Uroplakin. Others newer marker used in diagnosing 
prostatic origin are Prostein and NKX3.1 
CD 10 MARKER: 
CD 10 commonly called as CALLA antigen is a neutral endopeptidase 
present on many cell surface. Their major function is to inactivate biopeptides 
(20). It is widely used as cell surface marker for categorizing acute leukemia 
and malignant lymphomas. It is expressed by germinal center B cells, and 
lymphoid precursor cells. The role and expression of CD10 in non 
hematolymphoid tissue in both normal and pathological state has been well 
documented in many literatures. 
CD 10 IN NORMAL TISSUE: 
 Normal Tissue in Which CD10 Antigen Was Detected are 
myoepithelial cells of breast and in apocrine metaplasia of breast tissue, apical 
surface of normal epithelial cells of small and large intestines (25), glomerular 
cells and proximal convoluted tubules of kidney, Apical surface of large 
prostate ducts (23), Apical surface of epididymalducts, Endometrial stromal 
cells (26), Bone marrow stromal cells, Liver canaliculi (24) and alveolar 
epithelial cells in lung (21) 
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CD10 IN HEMATOPOIETIC TUMORS: 
 CD10 is used as a diagnostic marker in B-lymphoblastic leukemia/ 
lymphoma and in mature B-cell lymphomas like plasma cell myeloma, 
follicular lymphoma, diffuse large B-cell lymphoma and Burkitt lymphoma 
and very rarely in T-cell lymphoma. 
CD 10 positivity in B cell lymphoma indicates a good prognosis. Such 
patients receive less intensified chemotherapy, proving it to be prognostic 
marker as well.(27) 
CD10 IN SOLID TUMORS 
From the extensivestudies on CD10, it was revealed that CD10 is 
notspecific to hematopoietic malignancies but is also expressed by several non 
hematopoietic tumors such as solid tumors of childhood like nephroblastoma 
and neuroblastoma (28), and in several carcinomas originating from kidney 
(30), lung (31), pancreas (33), prostate (34), liver (35), breast (36), stomach 
(37), cervix (36), and bladder (38), Malignant melanoma (29) and various 
other skin tumors (32) also show CD10 positivity. 
ROLE OF CD 10 IN EPITHELIAL CELLS: 
 CD 10 is a transmembrane enzyme present over the surface of epithelial 
cells has got dual functions. 
 The extracellular portion of CD10 has peptidase enzymatic activity 
which cleaves the several peptides like endothelin, bombesin, enkephalin etc. 
These cleaved peptides can either activate or inactivates the stem cells 
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resulting in either proliferation and differentiation towards the epithelial cell 
lineage or it can be inhibited from proliferation. 
 
Figure 11: CD10 structure and function 
 
 The intracellular portionof CD10 governs major signaling pathway that 
are required for cell proliferation. Thus it can integrate signals from 
extracellular and intracellular compartment and can bring important changes in 
the cells according to the microenvironment present around the cells. 
ROLE OF CD 10 IN NORMAL PROSTATE: 
In normal prostate gland CD 10 is expressed by luminal epithelial cells. 
Some studies state that it also expressed by basal cell layer of prostate (39) 
.This strongly signifies the role of CD 10 that it cleaves excessive peptides 
thus preventing and controlling the unwanted proliferation of epithelial cells. 
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ROLE OF CD10 IN PROSTATE CANCER: 
 CD10 is strongly expressed by normal prostatic luminal epithelial cells. 
Primary tumors of the Prostate especially adenocarcinoma shows different 
pattern of expression of CD10 .Low Gleason grade tumors shows  loss of 
expression whereas high Gleason grade tumors shows altered and strong 
expression. The expression of CD10 is cytoplasmic when compared to apical 
membranous of normal epithelial cells. Cytoplasmic accumulation of CD10 
may activate signaling pathway constantly leading to uncontrolled 
proliferation and invasion. But the hypothesis has not been proved yet (60)  
MOLECULAR ANALYSIS OF CD 10 EXPRESSION IN PROSTATE: 
The neutral endopeptidase or CD10 gene was analysed by several 
molecular studies including tissue microarray, human cell lines study in 
vitro and in vivo etc. It was identified that transcription of this gene is 
androgen hormone mediated in prostate cancer cells. They have also identified 
in the NEP gene an androgen responsive element (NEP-ARE) and an 
androgen responsive region (NEP-ARR) suggesting the role of androgen ion 
their expression. Thus both the regions are involved in the transcriptional 
activation of CD10. (41). 
After transcription, translation of CD10 is enhanced by methylation of 
gene promoter (42). There is evidence of hypermethylation of gene promoter 
in case of high grade carcinoma suggesting a role of promoter region 
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mutation. So far no studies have demonstrated the mutations in CD10 gene per 
se.  
It has been well analysed that CD 10 is expressed in the membranes of 
prostatic cells. High grade tumors of prostate showed cytoplasmic positivity 
and low grade tumors shows absence of expression. This variation in 
cytoplasmic localization of CD10  possibly due to following mechanisms:  
1. Internalization of membrane bound CD10 (43) 
2. Strong association of CD10 with intracytoplasmic heat shock 
proteins.(44) 
The reason for absence of its expression in low grade tumors is not well 
understood. 
 Most lymph node metastases of prostatic carcinomastrongly express  
CD10 positivity in the malignant epithelial cells thus contributing to the fact 
that it could be involved in the  pathogenesis of lymph node metastasis.(39). 
High CD10 expression directly correlates with advanced Gleason score, 
and thus tumor expressing CD10 may be considered aggressive tumors with 
poor pathological outcome. 
Because of the strong association of CD10 with high grade tumors and 
in lymph node metastasis one can consider the possibility that CD10 can be 
used to categorise the lesion as aggressive and such patients can be closely 
followed up for lymph node metastasis. 
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Anti CD10 drug therapy can also be used to treat the patients, if its 
exact role in the pathogenesis is identified.  
An immunohistochemistry based test can be used in the clinical setting 
to identify CD10-positive tumors on prostate needle biopsies, which may 
warrant more aggressive initial therapy or closer surveillance post-operatively. 
 A number of drugs against CD10 are available and potential targeted 
therapies could be formulated based on these drugs, including monoclonal 
antibody mediated-delivery of chemotherapy. 
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MATERIALS AND METHODS  
 
Study Place: Department of Pathology, Chengalpattu Medical College and 
Hospital, Chengalpattu. 
Study Design: The present study is an observational study  conducted in the 
Department of Pathology during the period of June 2012 to May2016 . 
Ethical clearance for the study was obtained from the Institutional 
Ethics Committee of Chengalpattu Medical College, Chengalpattu. 
A total sample of 40 cases of prostatic lesions was analyzed during the 
period of June 2012 to May 2016. 
Study Population  
INCLUSION CRITERIA  
Tissue blocks of patients who are diagnosed as having benign and 
malignant prostatic lesions. 
EXCLUSION CRITERIA: 
Tissue blocks of patients who are diagnosed as prostatic carcinoma and 
underwent preoperative Radiotherapy or Chemotherapy. 
During the period of June 2012 to May 2016, as per the inclusion and 
exclusion criteria, biopsies received in the Department of Pathology were 
included. 
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History written in the histopathology request form was recorded on 
predesigned and pretested proforma (Annexure I).  
MATERIALS USED 
Tissue sections prepared from paraffin embedded formalin fixed tissues  
Haematoxylin and eosin staining kit  
CD 10 monoclonal antibody kit 
Secondary antibody kit  
Positive control  
Negative control 
METHOD:  
 Formalin fixed paraffin embedded blocksand haematoxylin eosin 
stained sections of 40 prostatic biopsies are taken up for the study. On 
histopathological examination, they were categorized as follows: 
1. Benign prostatic hyperplasia,  
2. Benign prostatic hyperplasia with prostatitis 
3. Prostatic intraepithelial neoplasia high grade and low grade, 
4. Prostatic adenocarcinoma. 
  Prostatic adenocarcinoma was assigned Gleason grade ranging from 
grade 1 to grade 5 according to modified Gleason grading system. 
 Immunohistochemistry was performed on the tissue sections taken 
from the blocks along with positive and negative control. 
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Immunohistochemistry  
Procedure  
1. 4μ thick sections were cut from formalin fixed paraffin embedded 
tissue samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight.  
3.  The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4.  Rehydrated through descending grades of alcohol as follows : 
(i)Absolute alcohol x 2 changes 5 minutes each  
(ii) 90% alcohol x 5 minutes 
(iii) Washed in distilled water 2 changes, 2 minutes each  
5. Heat induced antigen retrieval was done with microwave oven at 150 
degree Celsius with citrate buffer (pH 6.0) for 15 to 20 minutes.  
6.  Then cooled for 10 minutes.  
7.  Washed in distilled water 2 changes, 2 minutes each.  
8. Washed in Tris Buffer Saline (TBS) for 2 minutes. 
9.  Endoperoxidase blocking was done by adding hydrogen peroxide on 
the section and kept for 5 minutes. 
10. Washed in the wash buffer for 2 minutes twice. 
11. Primary antibody CD 10(Mouse monoclonal;prediluted) was added and 
kept for 30 minutes in a moist chamber.  
12. Then washed in wash buffer 2 minutes 2 times each.  
13. Poly excel target binder reagent was added and kept for 15 minutes.  
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14. Washed in two changes of buffer 2 minutes each. 
15. Poly excel HRP (Horse Radish Peroxidase) was added and incubated 
for 15 minutes.  
16. Washed with buffer – 2 minutes, 2 changes.  
17. Working DAB Dchromogen (1ml DAB buffer + 1 drop chromogen, 
mix well) was added and kept for 2-5 minutes. 
18. Then washed in distilled water.  
19. Counter stained with hematoxylin for 30 seconds.  
20. The slides were washed in running tap water for 3 minutes.  
21. The slides were air dried, cleared with xylene and mounted with DPX.  
Positive control included blocks containing normal prostatic gland- 
internal control Negative control included Primary antibody replaced 
with PBS.    
Immunostained sections were reviewed for CD 10 expression 
CD10Expression: 
1. CD 10 immunoreactivity was observed and assigned as positive or 
negative. 
2. CD 10 immunreactivity was analysed for pattern of expression. 
Pattern of expression as follows: 
1. Apical membranous positivity 
2. Diffuse membranous positivity 
3. Membranous and cytoplasmic positivity 
4. Cytoplasmic positivity 
5. Negative 
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STATISTICAL ANALYSIS 
 
Datas obtained were coded and entered into the Microsoft excel spread 
sheet (Annexure II). Datas were compared between groups using Pearson Chi-
square or Fisher‘s exact tests (p<0.05). 
All statistical analysis was performed using SPSS statistical software 
version 11. Charts were prepared using Microsoft excel 2007. 
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OBSERVATION AND RESULTS 
 
We took a sample size of 40. Among the 40 cases .We have the 
following distribution 
15 cases - Benign prostatic hyperplasia 
15 cases -Prostatic adenocarcinoma 
 5 cases - Benign prostatic hyperplasia with prostatitis,and  
5 cases - Prostatic intraepithelial neoplasia. 
The case distribution is represented as follows 
 
AGE WISE DISTRIBUTION OF PROSTATIC LESION:  
The age wise distribution of prostatic lesions in the present study 
showed the following observations. 
For benign prostatic hyperplasia majority of the patients are in the age 
group of 60 – 80 years. 
Benign prostatic hyperplasia with prostatitis, 70 – 80 years 
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Prostatic intraepithelial neoplasia - 60 – 80 years 
Prostatic adenocarcinoma - 60 – 70 years. 
The mean age group for various lesions is as follows 
Benign prostatic hyperplasia–67years 
Benign prostatic hyperplasia with prostatitis-70years 
Protatic intraepithelial neoplasia –66yearsand  
Prostatic carcinoma -68years. 
 
 
 
Age Vs 
HPE 
Benign 
Prostatic 
Hyperplasia 
% BPH  with Prostatitis % 
Prostatic 
Intraepithelial 
Neoplasia 
% 
Prostatic 
Adenocarcin
oma 
% 
≤ 50 years 1 6.67 0 0.00 1 20.00 0 0.00 
51-60 years 3 20.00 1 20.00 1 20.00 4 26.67 
61-70 years 5 33.33 1 20.00 1 20.00 7 46.67 
71-80 years 5 33.33 3 60.00 1 20.00 2 13.33 
81-90 years 1 6.67 0 0.00 1 20.00 2 13.33 
Total 15 100 5 100 5 100 15 100 
 
 
1
0
1
0
3
1 1
4
5
1 1
7
5
3
1
2
1
0
1
2
0
1
2
3
4
5
6
7
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Benign Prostatic
Hyperplasia
Benign  Prostatic
Hyperplasia with
Prostatitis
Prostatic
Intraepithelial
Neoplasia
Prostatic
Adenocarcinoma
Chart 2: Age Vs Histopathological diagnosis
≤ 50 years 51-60 years 61-70 years 71-80 years 81-90 years
51 
 
Table 1: Age and histopathological diagnosis 
HPE 
Distribution 
Benign 
Prostatic 
Hyperplasia 
BPH with 
Prostatitis 
Prostatic 
Intraepithelial 
Neoplasia 
Prostatic 
Adenocarcinoma 
Mean 67.93 70.80 66.80 68.47 
SD 10.26 7.85 12.83 9.53 
P value  
Single Factor ANOVA Test 0.9307 
                                    
GLEASON SCORE AND PROSTATIC ADENOCARCINOMA : 
 The prostatic carcinoma cases were scored according to Gleason score 
as<3+3, 3+4, 4+3, >4+4. Their distribution as follows:  
Table 4: Gleasons score and prostatic carcinoma. 
Gleason Score  Prostatic Adenocarcinoma % 
<3+3 6 40.00 
3+4 2 13.33 
4+3 3 20.00 
>4+4 4 26.67 
Total 15 100 
 
6 cases were having the score of <3+3 
 2 cases were having the score of 3+4  
 3 cases were having the score of 4+3  
           4 cases were having the score of >4+4 . 
Their percentage is represented as follows: 
Among the study cases 40% showed Gleason score <3+3, 26% showed 
Gleason score >4=4, 20 % showed with Gleason score 4+3, and 13.33% 
showed with Gleason score 3+4. 
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SERUM PSA LEVEL AND PROSTATIC CARCINOMA: 
We collected Serum PSA level from the patients with prostatic 
carcinoma. The cases were categorised as follows 
 
Table 5: Serum PSA level vs prostatic carcinoma 
Serum PSA Levels Prostatic Adenocarcinoma % 
< 10 ng/ml 0 0.00 
10 – 20 ng/ ml 7 46.67 
>20 ng/m 8 53.33 
Total 15 100 
 
 
 
40%
13%
20%
27%
Gleason Score Vs Prostatic Carcinoma
<3+3 3+4 4+3 >4+4
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In our present study,  
There were no cases under  <10 ng/ml, 
There were 7 cases under the range of 10 – 20 and  
There were 8 cases coming under range of >20 ng /ml. 
The percentage of cases are 46.67% in the range of 10 – 20ng/ml, and 
53.33% for >20 ng/ml. 
 
SERUM PSA LEVEL AND GLEASON SCORE: 
Analysing serum PSA levels with Gleason score we had the following 
results 
Serum PSA level 10 – 20ng/ml,  
Gleason score <3+3 - 83.33%  
Gleason score  3+4-  Nil cases 
Gleason score 4+3 - 33.33% and  
Gleason score>4+4. - 25%  
0, 0%
7, 47%
8, 53%
Serum PSA Levels Vs Prostatic Carcinoma
< 10 ng/ml 10 – 20 ng/ ml >20 ng/m
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For serum PSA level more than 20 ng/ml, we have the following percentage 
Gleason score<3+3 - 16.67%  
Gleason score  3+4-  100% 
Gleason score 4+3 -  66.67%  and  
Gleason score>4+4. - 75%  . 
Using fischers exact test increases serum PSA level shows strong 
association with high Gleason score with the P value being <0.001 
 
 
Table 6: Serum PSA level vs Gleason score 
Serum PSA 
Levels Vs 
Gleason Score 
<3+3 % 3+4 % 4+3 % >4+4 % 
< 10 ng/ml 0 0.00 0 0.00 0 0.00 0 0.00 
10 – 20 ng/ ml 5 83.33 0 0.00 1 33.33 1 25.00 
>20 ng/m 1 16.67 2 100.00 2 66.67 3 75.00 
Total 6 100 2 100 3 100 4 100 
P value  
Fishers Exact Test 
<0.0001 
 
0 0 0 0
5
0
1 11
2 2
3
0
2
4
6
<3+3 3+4 4+3 >4+4
Serum PSA Levels Vs Gleason Score
< 10 ng/ml 10 – 20 ng/ ml >20 ng/m
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AGE AND GLEASON SCORE: 
 In our present study we analysed the age wise distribution of Gleason 
score. The distribution and mean age group for the different gleason score are 
as follows. 
For Gleason score<3+3 the mean age group is 68 years 
For Gleason score 3+4 the mean age group is 62 years 
For Gleason score 4+3 the mean age group is 66 years 
For Gleason score >4+4 the mean age group is 73 years. 
Age Vs Gleason Score <3+3 % 3+4 % 4+3 % >4+4 % 
≤ 50 years 0 0.00 0 0.00 0 0.00 0 0.00 
51-60 years 1 16.67 0 0.00 1 33.33 1 25.00 
61-70 years 4 66.67 2 100.00 1 33.33 1 25.00 
71-80 years 0 0.00 0 0.00 1 33.33 1 25.00 
81-90 years 1 16.67 0 0.00 0 0.00 1 25.00 
Total 6 100 2 100 3 100 4 100 
 
Table 7: Age vs Gleasons score 
Age Vs Gleason Score Distribution <3+3 3+4 4+3 >4+4 
Mean 68.33 62.50 66.67 73.00 
SD 10.29 3.54 7.64 12.25 
P value  
Single Factor ANOVA Test 0.8036 
 
Gleasons score <3+3 and 3+4 Gleason score was observed 
predominantly in the age group of 61 – 70 years constituting 66.67% and 
100% respectively.Gleason score 4+3 and 4+4  shows equal distribution of age 
groups each constituting about 33.33% and 25 % respectively.. 
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DIFFERENT PROPORTION OF GLEASON GRADE AMONG 
PROSTATIC CARCINOMA:  
We also analysed the percentage of Gleason grade 2, 3, 4 and 5 among 
the total sample of 15 malignant lesions. Their percentage are as follows 
Grade 2 – 7% 
Grade 3 – 53% 
Grade 4 – 34% 
Grade 5 – 7% 
 In our study Gleason pattern 3 form major proportion of cases. 
0 0 0 0
1
0
1 1
4
2
1 1
0 0
1 11
0 0
1
0
1
2
3
4
5
<3+3 3+4 4+3 >4+4
Age Vs Gleason Score
≤ 50 years 51-60 years 61-70 years 71-80 years 81-90 years
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 We also analysed the different combinations among various Gleason 
pattern.  The results are as follows: 
Table 8: Different combination of Gleason pattern 2,3,4,5 
Gleason Score 
Expression 
Grade 
2 % 
Grade 
3 % 
Grade 
4 % 
Grade 
5 % 
Grade 2 0 0% 1 7% 0 0% 0 0% 
Grade 3 2 13% 3 
20
% 2 
13
% 1 7% 
Grade 4 0 0% 3 20% 1 7% 1 7% 
Grade 5 0 0% 1 7% 0 0% 0 0% 
 
IMMUNOOHISTOCHEMICAL EXPRESSION IN BENIGN AND 
PREMALIGNANT LESIONS: 
Regarding the immunohistochemical expression of CD10 in benign and 
premalignant lesions the results are as follows. In case of benign prostatic 
hyperplasia 73% showed apical membranous staining whereas only 13%   
showed diffuse membranous staining and 7% cytoplasmic staining. The 
13%
7%
20%
20%
7%
13% 7%
7% 7%
0%
20%
40%
60%
80%
100%
Grade 2 Grade 3 Grade 4 Grade 5
Gleason Score Expression
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staining pattern is only apical membranous in all the 5 cases of BPH with 
prostatitis. In case of PIN 20% showed diffuse membranouspositivity, 
predominantly around 60 % showed both membranous and cytoplasmic 
positivity and 20 % showed only cytoplasmic positivity.. This showed a 
significant correlation with p value <0.0021 
 
Table 3: Immunohistochemical diagnosis vs benign and premalignant 
lesions 
IHC Diagnosis 
Vs Benign and 
Premalignant 
Lesions 
Benign 
Prostatic 
Hyperplasia 
% 
Benign  
Prostatic 
Hyperplasia 
with 
Prostatitis 
% 
Prostatic 
Intraepithelial 
Neoplasia 
% 
Negative 0 0.00 0 0.00 0 0.00 
Apical 
Membranous 
Positivity 
11 73% 5 100.00 0 0.00 
Diffuse 
Membranous 
Positivity 
2 13% 0 0.00 1 20.00 
Membranous 
and 
Cytoplasmic 
Positivity 
1 7% 0 0.00 3 60.00 
Cytoplasmic 
Positivity 
1 7% 0 0.00 1 20.00 
Total 15 100 5 100 5 100 
P value  
Fishers Exact Test 
0.0021 
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GLEASON GRADE AND CD10 EXPRESSION: 
Having been categorized the malignant lesions of prostate  according to 
the age, Gleason score, and serum PSA levels, we also analysed the 
immunohistochemical pattern of expression of CD 10 and its significance with 
different Gleason score and serum PSA levels. 
All the prostatic carcinoma cases were graded according to the Gleason 
grade and the percentage of each grade was estimated. We had the following 
results: 
 Out of 15 cases grade 3 component was seen in 13 cases, grade 4 
component in 7 cases, grade 2 and grade 5 component in 3 cases each. The 
percentage of staining in each pattern was estimated.  We observed the 
following results. 
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Table 9: Gleason grade vs. CD10 expression 
Gleason 
Grade Vs 
CD 10 
Expression 
Negative 
Apical 
Membranous 
Positivity 
Diffuse 
Membranous 
Positivity 
Membranous 
and 
Cytoplasmic 
Positivity 
Cytoplasmic 
Positivity Total 
Grade 2 3 0 0 0 0 3 
grade 3 10 3 0 0 0 13 
grade 4 2 0 0 0 5 7 
Grade 5 0 0 0 0 3 3 
P value, Fishers Exact Test 0.0021 
 
Analysing the expression of CD10 all the grade 2 components showed 
absence of expression (100%), 76.92% of grade 3 componentsshowed absence 
of expression and 23.07% showed apical membranous positivity.None of the 
grade 3 lesions showed combined and cytoplasmic positivity. Among grade 4 
lesions 71.43% showed intense cytoplasmic positivity and 28.57% showed 
absence of expression. All cases of grade 5 lesions (100%) showed diffuse 
cytoplasmic positivity with intense staining pattern. 
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SERUM PSA LEVEL AND CD10 EXPRESSION:  
 In the present study we classified the serum PSA level of the prostatic 
carcinoma cases as <10ng/ml, 10-20 ng/ml, >20ng/ml.     
CD 10 expression also varied depending upon the PSA level.  
In the PSA range of 10 – 20 ng/ml 
 4 cases showed absence of expression 
 2 cases showed apical membranous positivity and     
1 case with cytoplasmic positivity.  
In cases with serum PSA level >20ng/ml, we had 
 2 cases withneagtive expression 
 1 case with apical membranous positivity 
 5 cases with cytoplasmic positivity. 
3
10
2
3
5
3
0
2
4
6
8
10
12
14
Grade 2 grade 3 grade 4 Grade 5
Gleason Grade Vs CD 10 Expression
Negative Apical Membranous Positivity
Diffuse Membranous Positivity PMembranous and Cytoplasmic Positivity
Cytoplasmic Positivity
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Table 11: Serum PSA level vs CD 10 expression 
Serum PSA 
Levels Vs CD 
10 Expression 
Negative 
Apical 
Membranous 
Positivity 
Diffuse 
Membranous 
Positivity 
Cytoplasmic 
Positivity Total  
< 10 ng/ml 0 0 0 0 0 
10 – 20 ng/ ml 4 2 0 1 7 
>20 ng/m 2 1 0 5 8 
P value , 
Fishers Exact Test 0.0492 
 
 
As the serum PSA level increases there is a shift from negative 
expression to cytoplasmic expression. P value showed significant association 
between increased serum PSA and increased cytoplasmic expression. 
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Colour plate 1: H&E, Benign prostatic hyperplasia, 10x 
 
Colour plate 2: H&E, Benign prostatic hyperplasia with prostatitis, 10x 
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Colour plate 3: H&E, Prostatic intraepithelial neoplasia, 10x. 
 
Colour plate 4: H&E, Gleason grade 3, 10x. 
65 
 
 
Colour plate 5: H&E, Gleason grade 4 (hypernephroid pattern), 10x 
 
Colour plate 6: H&E, Gleason grade 5, 40x 
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Colour plate 7: CD10 positivity, Benign prostatic hyperplasia, 10x 
 
Colour plate 8: CD10 positivity, Apical membranous staining 
in benign glands, 40 
67 
 
 
Colour plate 9: CD 10 Positive, Diffuse membranous positivity, 40x 
 
Colour plate 10: CD10 negative, neoplastic acinar glands, 10x 
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Colour plate 11: CD10 negative, Gleason grade 3, 40x. 
 
Colour plate 12 : CD10 positive,  Gleason grade 4, 10x 
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Colour plate 13: CD10 positivity, Gleason grade 4, cytoplasmic positivity, 
40x 
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DISCUSSION 
 Prostatic lesions whether it is a nonneoplastic or neoplastic are 
responsible for significant morbidity and mortality among the males 
worldwide (1). Of all the lesions, prostatic carcinoma causes significant 
mortality and has to be viewed seriously. It has got long indolent course with 
varied presentations ranging from asymptomatic, urinary outflow obstruction 
to widespread lymph node and skeletal metastasis. 
Our study is an attempt to use a hematological marker CD10 and to 
evaluate its expression and significance in various lesions of prostate. CD 10 
is a transmembrane ectopeptidase which generally cleaves the peptides is 
thought to have a role in prostatic cancer. 
Based on the fact that variety of CD antigens was used to identify and 
classify several leukemias, we are keen in knowing whether the same could be 
applicable for prostatic lesions also. 
On comparing age wise distribution of prostatic carcinoma with other 
studies we had only one case with similar comparison. 
Only study by Achim Fleischman et al., analysed age wise distribution 
of prostatic carcinoma cases. He had predominant cases of 1807 in the age 
range of 60 – 70 years, contributing 59%. In our study we also had maximum 
number of cases in the age group of 61 – 70 years contributing 46.67% of total 
prostatic carcinoma cases. 
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Table 11: Age wise distribution of prostatic carcinoma cases – 
Comparison 
 
 
       Our study 
Age range Number of cases Percentage of cases 
51-60 years 4 26.67 
61-70 years 7 46.67 
71-80 years 2 13.33 
81-90 years 2 13.33 
 
 
 Achim 
Fleischman. et al 
<50 83 2.7% 
50 – 60 998 32.6% 
60 – 70 1807 59% 
>70 175 5.7% 
 
Similarly by analysing Gleason score wise distribution of prostatic 
carcinoma cases with study by Achim Fleischman et al., we had the following 
comparison: 
Our study 
Gleason score Number of cases Percentage 
<3+3 6 40% 
3+4 2 13% 
4+3 3 20% 
>4+4 4 26.6% 
Achim 
Fleischman. et al 
<3+3 1426 45.9% 
3+4 1311 42.2% 
4+3 313 10.1% 
>4+4 55 1.8% 
 
 In our present study majority of the cases 40% are under Gleason score 
<3+3 which is similar to Achim Fleischman et al., study who had 45.0% under 
Gleason score <3+3.  
It clearly indicates that benign, preneoplastic and neoplastic lesions 
show different expression patterns from the statistical analysis. 
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In our study it was observed that in normal glands and in benign 
prostatic hyperplasia CD 10 showed intense apical membranous staining. Very 
few glands showed circumferential membranous staining also and even less 
than 1% showed granular cytoplasmic positivity. The complete membranous 
staining by epithelial cells produced a honey comb appearance. Some of the 
glands also showed staining of corpora amylacea of varying intensity. Since 
we are considering about the luminal epithelial cells all other findings was not 
seriously analysed. 
Study conducted by Peiguochu et al (29) concludes that CD10 
expression wasseen in luminal epithelial cells and ductal epithelial cells of 
normal prostatic gland.It was the first study to analyse the expression of CD10 
in nonhematopoietic tissues including normal and pathological forms. But he 
didn’t mention about the pattern of expression in such cells. 
Complete membranous staining was observed in benign 
prostatichyperplastic and normal glands in the study of Iman Osman et al (40). 
He didn’t stress about the apical membranous positivity. 
Sherif Tawfic et al., (38) study showed similar results to our study. In 
our study normal prostatic glands and benign hyperplastic glands shows 
similar pattern of expression when compared with his study. But he also stated 
that CD 10 expression in addition to luminal epithelial cells is also seen in 
basal cells. The cytoplasm and membrane of basal cells in benign glands 
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shows CD10 positivity. He uses this feature of basal cell positivity in 
differentiating benign and malignant lesions of prostate.. 
 We also observed that in prostatitis cases there is no alteration in the 
CD10 pattern of expression of hyperplastic glands. All glands showed intense 
apical membrane staining pattern. So we can conclude that inflammation 
adjacent to the glands doesn’t change the expression pattern in the 
hyperplastic glands. No other studies have considered CD 10 expression in 
prostatitis. So our results could not be compared. 
In case of Prostatic intraepithelial neoplasia there is a variable 
expression pattern of CD10.  We included 2 cases of low grade PIN and 3 
cases of high grade PIN. Low grade PIN showed diffuse membranous 
positivity whereas high grade PIN showed negative in 2 cases and diffuse 
cytoplasmic positivity in 1 case.It is well known that low grade PIN does not 
carry any risk for subsequent development of carcinoma. The expression 
pattern also displayed same feature as that of benign glands. No other study 
has taken low grade PIN into consideration. 
There are 3 case studies which showed absence of CD10 expression in 
high grade PIN. Studies by Freedland et al (58) and Zellweger et al (59).on 
tissue microarray of radical prostatectomy samples showed absence of 
membranous positivity in High grade PIN. Study by Sherif tawfic et al (38) 
analysed twelve cases of PIN also showed absence of diffuse membranous and 
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cytoplasmic expression of CD 10 in all the cases. Our study also showed 
absence of membranous positivity in 2 cases.  
Thus when we analyse the CD 10 expression in benign and 
premalignant lesions of prostate it was clearly observed that there is a 
progressive loss of membranous CD10 expression thus signifying its role in 
the pathogenesis from benign to premalignant conditions. In normal glands 
and in benign conditions the extracellular peptidase activity of CD10 cleaves 
the unwanted peptides that could acts as a growth factor for the cells, thereby 
controlling the cell proliferation (23). In case of intraepithelial lesion their 
absence of expression leads to loss of cleavage activity thereby resulting in 
uncontrolled proliferation of cells 
Analysing the expression of CD10 in various grades of prostatic 
carcinoma, we have heterogenous expression in different grades. In our study 
almost all the neoplastic acinar glands showed complete membranous and 
cytoplasmic loss of CD 10 expression in Gleason grade 2 and Gleason grade 3. 
It is important to mention that in all the grade 2 and grade 3 lesions the 
adjacent benign glands shows typical membranous positivity. Thus we can 
easily distinguish benign from the malignant counterparts even at a lower 
magnification itself. 
Sherif tawfic et al (38) and Mellisa et al (61) in their study, also 
observed similar pattern of expression in low grade tumors (grade 2 and 3). 
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Study by Achim Fleischmann et al (60) showed variable expression patterns in 
grade 3. In his study he observed that 40 % of grade 3 lesions showed total 
absence of expression, whereas 30 % showed membranous expression and few 
cases showed cytoplasmic expression. 
 In our study we observed that malignant cells of Gleason pattern 4 and 
5 showed increased cytoplasmic expression (71% and 100%) respectively. In 
all the cases the adjacent normal glands showed membranous positivity and 
therefore the pattern of expression is easily compared.It is evident that there is 
a sharp alteration in the subcellular localisation of CD10, shifting from 
membranous in benign to cytoplasmic in malignant. Among the malignant 
lesions there is again a shift from absence of expression in lower grade to 
increased expression in higher grade.  
Table 11: Gleason grade and CD 10 expression- comparison 
Our study 
Gleason 
Grade  Negative 
Apical 
Membranous 
Positivity 
Membranous 
and 
Cytoplasmic 
Positivity 
Cytoplasmic 
Positivity P value 
Grade2 100% 0 0 0 
0.0021 Grade 3 76.92% 23.07% 0 0 Grade 4 28.57% 0 0 71.43% 
Grade5 0 0 0 100 
Achim 
Fleischmann 
Gleason 
score Negative 
Apical 
Membranous 
Positivity 
Membranous 
and 
Cytoplasmic 
Positivity 
Cytoplasmic 
Positivity P value 
<3+3 53.5 34.1 18 4.3 
<0.0001 3+4 46 27.1 22.1 4.8 4+3 33.5 26.5 25.9 14.1 
>4+4 36.4 10.9 23.6 29.1 
Iman Osman, 
Gleason 
score Negative Heterogenous  Positive P value 
<7 45.9 18 36.1 0.700 >7 48.5 13.9 37.6 
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Sherif tawfic et al (38) in his study observed that in higher Gleason 
pattern 4 and 5 neoplastic cells arranged in glandular pattern showed absence 
of expression whereas infiltrating cells, single cells and cribriform pattern 
showed cytoplasmic expression. He insisted that the histopathological pattern 
of malignancy determines the CD10 expression rather than higher grade of the 
tumor (Gleason pattern 4 and 5). 
 Osman et al. (40), in his study, divided primary prostatic carcinoma 
into two groups based on Gleason score as < 7 and >7. He observed that both 
the groups <7 and >7 Gleason score showed predominantly absence of 
expression in 45.9% and 48.5% respectively. He mainly analysed the presence 
or absence of CD10 expression and their association with PSA recurrence 
during follow up. 
There are handful of reasons for the altered expression of CD10 in 
various lesions of prostate. Most of them are only hypothesis arrived by 
prostate cancer cell specific microarray studies. 
One such study by Usmani et al.,(63) stated that the loss of CD 10 
expression could be due to hypermethylation of promoter region. After 
transcription, translation is necessary for the synthesis of protein. When there 
is hypermethylation in the promoter region during the process of translation  
CD 10 synthesis cannot take place thereby resulting in reduced expression in 
case of PIN (preneoplastic lesion) to absence of expression in the next stage of 
77 
 
disease progression (Gleason pattern 2 and 3). Thus thishypothesis explained 
the possibility of reduced expression in high grade PIN to absent of expression 
in early stage of tumor. 
The cytoplasmic localization of Cd10 in high grade could be due to 
increased bound forms of CD10 with cytoplasmic heat shock proteins.This 
intracytoplasmic accumulation drives the cell to constant signaling pathway 
that is independent of the growth factor signaling (64) 
Marc A Dall'Era, Achim Fleischmann et al (60), Melissa E Ho et al 
(61) studied the association of CD10 expression and lymph node metastasis as 
well as with recurrence free survival. All the studies concludes that increased 
expression of CD10 is associated with high grade tumors, lymph node 
metastasis and also with decreased recurrence free survival. 
This is contradictory to the study by Sumitomo M eta l (62) who proves 
that CD 10 inhibits cell migration in prostate cancer. This is strongly against 
the possibility of Cd10 expression and lymph node metastasis.  
Dall’Era et al (65) .and Achim Fleischmann et al (60) suggested that 
CD10 expression in malignant lesions of prostate is an unfavorable risk factor 
for carcinoma prostate. Achim Fleischmann et al also added that PSA 
recurrence–free survival significantly declines from membranous over 
membranous-cytoplasmic to exclusively cytoplasmic CD10 expression. 
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In contradicting the above studies, Osman et al (40) observed  that loss 
of CD10 expression is associated with an unfavorable patient outcome. He 
stated that complete loss of CD10 expression was associated with PSA 
recurrence after radical prostatectomy. He  also stated that person with 
prostate cancer showing complete loss of expression are 2 times at a higher 
risk for relapse. Thus he concludes that absence of CD10 expression is an 
independent risk factor for  relapse.  
Tissue micro array study by Melissa E Ho et al (61) who analysed the 
expression of two markers AGR2 and CD10 simultaneously in prostate cancer 
specimen observed that in case of PIN, the CD10 expression decreases. The 
author also analysed the association of CD10 expression with clinical outcome 
of the patient. He observed that cases with low CD10 expression have longer 
recurrence free survival. He hypothesised that downregulation of CD10 
expression in PIN andabsence of the same in low grade tumors strongly 
suggests its role in the tumor initiation and progression. 
Regarding serum PSA level and CD10 expression our study showed 
that as the PSA level increases there is a shift from absence to cytoplasmic 
expression of CD10 thereby concluding that increased serum PSA level is 
associated with increased cytoplasmic expression of CD10 in malignant 
glands. Thus Serum PSA level directly correlated with increased cytoplasmic 
positivity. 
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Table 12: Serum PSA level and CD10 expression – Comparison 
Our 
study 
Serum PSA 
Levels Negative 
Apical 
Membranous 
Positivity 
Diffuse 
Membranous 
Positivity 
Cytoplasmic 
Positivity P value  
< 10  0 0 0 0 
0.04 10 – 20  4 2 0 1 
>20  2 1 0 5 
Achim 
Fleisch
mann et 
al. 
Serum PSA 
level Negative 
Membranous 
Positivity 
Combined 
Positivity 
Cytoplasmic 
Positivity P value 
<4 57% 20.7% 8.1% 4.1% 
0.001 4 – 10 47.5% 27.4% 19.7% 5.4% 10 – 20  44.9% 23.9% 23.9% 7.3% 
>20  41.3% 25.3% 24.4% 8.9% 
Osman 
et al 
Serum PSA negative heterogenous expression  positive P value 
<5 14 13 11 
0.088 5 – 10 44 9 28 
>10 37 20 32 
 
We have a significant p value of 0.04 which is been correlated with 
other studies. Achinm et al (60) states that as the serum PSA level increases 
the absence of CD10 expression decreases and cytoplasmic positivity 
increases, with a positive p value of 0.001. 
Osman et al finding is contradictory from our findings. He states that 
there is no significant association Of CD10 with serum PSA value. His p value 
was 0.088. 
Finally we cannot expect the same role of CD10 in various tumors. In 
some tumors it inhibit their growth, for eg lung cancer and pancreas and in 
some it promotes their growth for eg liver and gastric cancer. Thus CD10 has 
tissue specific role and in the same tissue it can perform different functions at 
different phases of pathology. 
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Since many studies have strongly shown an association between CD10 
and outcome of prostate cancer, including disease free survival, lymph node 
metastasis etc. This can be used as a potential target for the treatment by anti 
CD10 drugs. CD 10 can also process peptide prodrugs due to their cleavage 
activity thereby increasing the drug concentration around the malignant cells 
and by promoting the drug cytotoxicity (66) 
By analyzing the CD10 expression on prostatic cancer biopsy specimen 
we can categorise the prostatic adenocarcinoma as high grade and low grade 
tumors. It will help to follow up high grade tumors for lymph node metastasis 
and guide to treat them more aggressively 
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SUMMARY 
Prostatic lesions causes significant morbidity and mortality among the 
elderly males worldwide. The symptoms due to prostate lesions whether 
benign or malignant are related to urinary symptoms, thus cannot be 
differentiating between these two entity. 
Our objective was to (i) identify and to analyse the expression of CD10 
in various lesions of prostate, (ii) to evaluate the expression of CD10 in the 
malignant lesions of prostate, (iii) to correlate the CD10 expression with age, 
histopathological grading, serum PSA level, of prostatic tumor cases. 
A total sample of 40 cases were analysed during the period of June 
2012 to May 2016.We categorized the total cases as benign, premalignant and 
malignant lesions, their age wise distribution was analysed. The cases of 
prostatic cancer was anlysed according to various Gleason grade, Gleason 
score, serum PSA levels. We performed IHC detection in sections of formalin 
fixed paraffin embedded tissue of prostatic biopsy cases and correlated the 
various patterns of CD10 expression among the different lesions of prostate 
with respect to histopathological diagnosis.  
In our study we found that benign prostatic hyperplasia showed 
predominantly apical membranous staining, BPH with prostatitis shows same 
apical membranous positivity, PIN showed differential expression with 
membranous positivity in low grade and absence to combined positivity in 
high grade PIN. In case of malignant lesions absence of expression in majority 
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of Gleason grade 2 (100%) and grade 3 (76%), cytoplasmic positivity 
predominance in high grade Gleason grade 4 (71%) and grade 5 (100%). 
Increased CD10 cytoplasmic expression is seen with  increased serum PSA 
levels (>20 ng/ml), with predominantly negative staining in serum PSA levels 
of 10 – 20 ng/ml. 
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CONCLUSION 
 
Our study is an observational study on “Analysis Of Immuno 
histochemical Expression Of CD10 In The Lesions Of Prostate was 
conducted in the Department of pathology from June 2012 to August 2016. 
Our study showed different pattern of expression of CD10 in various 
lesions of prostate. Apical membranous positivity in benign prostatic 
hyperplasia, same pattern of expression in BPH with prostatits, decreased 
membranous expression in high grade PIN, and altered expression in prostatic 
carcinoma. In low grade tumors we noted absence of expression, and in the 
high grade tumors we noted cytoplasmic expression. 
 Still the exact mechanism and the role of CD10 in the pathogenesis of 
prostatic carcinoma is under study, one of the hypothesis states that 
cytoplasmic positivity is due to localization of CD10 molecule  in the 
cytoplasm. This intracytoplasmic accumulation of CD10 drives the cell to 
constant signaling pathway leading to uncontrolled cell proliferation. Our 
study also favors this hypothesis as there is cytoplasmic expression in high 
grade tumors. 
In future this marker could be used as a diagnostic marker in 
differentiating benign and malignant lesions, to categorise the low grade and 
high grade tumors, and to determine the aggressive nature of the neoplasm.  
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ANNEXURE - I 
PROFORMA 
Date:   
1. Name     :         OP/IP No :                                                                            
2. Age         : 
3. Sex          :   Male  Female 
4. History  :     
5. Serum PSA level :  
Clinical Diagnosis  : 
Histopathological confirmation and grading of H&E stained section: 
1. Benign prostatic hyperplasia,  
2. Benign prostatic hyperplasia with prostatitis 
3.  Prostatic intraepithelial neoplasia high grade and low grade 
4.  Prostatic adenocarcinoma 
Gleason grade 2 
Gleason grade 3 
Gleason grade 4 
Gleason grade 5 
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CD10 expression 
Negative 
Positive 
 
Apical membranous 
Diffuse membranous 
Cytoplasmic 
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ANNEXURE II 
MASTER CHART 
1. AGE 
1. <60 
2. 60 – 70 
3. 71 – 80 
4. >80 
2. SEX 
1. Male 
3. HPE DIAGNOSIS: 
1. Benign prostatic hyperplasia 
2. Benign  prostatic hyperplasia with prostatitis 
3. Prostatic intraepithelial neoplasia. 
4. Prostatic adenocarcinoma. 
4. GLEASONS SCORE: 
1. <3+3 
2.  3+4 
3.  4+3 
4. >4+4 
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5. IHC DIAG- CD 10 EXPRESSION: 
0. Negative 
1. Apical membranous positivity 
2. Diffuse membranous positivity 
3. Membranous and cytoplasmic positivity 
4. Cytoplasmic positivity 
6. PRE OPERATIVE SERUM PSA LEVEL: 
1. < 10ng/ml 
2. 10 – 20 ng/ ml 
3. >20ng/ml 
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S.NO HPE NO Age  Sex Age group 
HPE 
diag 
Gleason 
score 
Serum.
PSA 
level 
IHC diag 
1. G750/16 46 1 1 1 nil nil 1 
2 G751B/16 86 1 4 1 nil nil 1 
3 G841/16 67 1 2 1 nil nil  2 
4 G890/16 80 1 3 1 nil nil 3 
5 G920/16 60 1 2 1 nil nil 1 and 4 
6 G923A/16 72 1 3 1 nil nil  2 
7 G919/16  60 1 2 1 nil nil 1 and 4 
8 G924/16 75 1 3 1 nil nil  2 
9 G1012/16 60 1 2 1 nil nil 1 
10 G925/16 62 1 2 1 nil nil 1 
11 G961/16 78 1 3 1 nil nil 1 
12 G962/16 65 1 2 1 nil nil 1 and 5 
13 G963/16 65 1 2 1 nil nil 1 
14 G964/16 78 1 3 1 nil nil 1 
15 G974/16 65 1 2 1 nil nil 1 
16 G948/15 66 1 2 2 nil nil 1 
17 G1017/15 75 1 3 2 nil nil 1 
18 G1381/15 80 1 3 2 nil nil 1 
19 G273/16 73 1 3 2 nil nil 1 
20 G975/16 60 1 2 2 nil nil 1 
21 G1367/13 50 1 1 3 nil nil 3 
22 1769/14 60 1 2 3 nil nil 3 
23 G1259/15 65 1 2 3 nil nil 4 
24 G211/16 81 1 4 3 nil nil 3 
25 G356/16 78 1 3 3 nil nil 2 
26 G775/12 65 1 3 4 1(3+2) 2 0 and 0 
27 G2/13 60 1 2 4 1(3+2) 2 0 and0 
28 G1317/13 75 1 3 4 3(4+3) 3 0 and1 
29 G316/14 65 1 2 4 3(4+3) 3 4 and 0 
30 G346/14 88 1 4 4 1(3+3) 2 0 and 0 
31 G564/14 60 1 2 4 3(4+3) 2 4 and 0 
32 G1182/14 66 1 2 4 1(2+3) 2 0 and 0 
33 G977/15 80 1 3 4 4(3+5) 3 0 and 4 
34 G1087/15 65 1 2 4 2(3+4) 3 0 and 4 
35 G1875/15 60 1 2 4 2(3+4) 3 0 and 4 
36 G67/15 61 1 2 4 1(3+3) 2 0 and 0 
37 G197/16 67 1 2 4 4(4+5) 2 4 and 4 
38 G421/16 70 1 2 4 1(3+3) 3 0 and 0 
39 G842/16 59 1 1 4 4(4+4) 3 4 and 4 
40 G960/16 86 1 4 4 4(5+3) 3 4 and 0 
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ANNEXURE – III 
GLOSSARY 
CD 10           :   Cluster of differentiation 
DAB      :   Di amino benzidine 
H&E           :   Haematoxylin & Eosin       
IHC         : Immunohistochemistry 
PBS  :  Phosphate buffer solution 
TBS  :  Tris buffer solution 
BPH  : Benign prostatic hyperplasia 
PIN   :   Prostatic Intraepithelial neoplasia 
DHT  : Dihydrotestosterone 
PSA    : Prsotate Specific Antigen 
IDC – P : Intraductal carcinoma prostate 
AMACR  : Alpha-methylacyl-CoA racemace 
WHO  :  World Health Organisation 
ISUP  :  International society of Urologic Pathology 
NEP  :  Neutral Endopeptidase 
NEP-ARE  : NEP gene an androgen responsive element 
NEP-ARR : NEP androgen responsive region  
CALLA : Common Acute Lymphoblastic Leukemia Antigen 
PSAP  : Prostate Specific Acid Phosphatase 
TURP  : Transurethral Resection of Prostate 
TMPRSS2 : Trans Membrane Protease Serine 2 
ERG  : ETS-related gene product 
ETS  : E26Transformation specific gene family 
 
